NCT01191177

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

An Initial Trial of Enteral Fish Oil Supplementation in the Treatment of Parenteral Nutrition-associated Liver Disease in Patients With Short Bowel Syndrome

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Boston Children's Hospital · Academic / Other
• Sex: All
• Age: 30 Days – 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the usefulness of oral fish oil(Lovaza)in normalizing liver function in patients who have parenteral nutrition associated liver disease. The investigators believe that patients who take oral fish oil will normalize liver function faster than those who do not

Detailed description

This is designed as a randomized placebo controlled trial of oral fish oil (Lovaza) in normalizing parenteral nutrition associated liver disease.

Conditions

• Liver Disease
• Short Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Lovaza (omega-3-acid ethyl ester)	supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
DIETARY_SUPPLEMENT	Corn oil	1 gram per kilogram body weight per day, not exceeding 4 grams

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2010-08-30
• Last updated: 2017-06-22

Locations

1 site across 1 country: United States